NO2563385T3 - - Google Patents

Info

Publication number: NO2563385T3
Authority: NO; Norway

Application number

NO11778000A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-28

Filing date

2011-04-28

Publication date

2017-12-30

2011-04-28 Application filed filed Critical

2017-12-30 Publication of NO2563385T3 publication Critical patent/NO2563385T3/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Marine Sciences & Fisheries (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO11778000A 2010-04-28 2011-04-28 NO2563385T3 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32907810P	2010-04-28	2010-04-28
PCT/US2011/034282 WO2011139820A1 (en)	2010-04-28	2011-04-28	Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number	Publication Date
NO2563385T3 true NO2563385T3 (de)	2017-12-30

Family

ID=44903987

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO11778000A NO2563385T3 (de)	2010-04-28	2011-04-28

Country Status (17)

Country	Link
US (1)	US8808697B2 (de)
EP (3)	EP2563385B1 (de)
JP (5)	JP5899206B2 (de)
KR (1)	KR20130086126A (de)
CN (2)	CN105381451B (de)
AU (1)	AU2011248540B2 (de)
CA (1)	CA2795823C (de)
DK (1)	DK2563385T3 (de)
EA (2)	EA036805B8 (de)
ES (2)	ES2826445T3 (de)
IL (1)	IL222739A0 (de)
NO (1)	NO2563385T3 (de)
NZ (1)	NZ603196A (de)
PL (2)	PL2563385T3 (de)
PT (2)	PT3260128T (de)
SG (1)	SG184907A1 (de)
WO (1)	WO2011139820A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130231464A1 (en) *	2010-04-28	2013-09-05	Oncolmmune, Inc.	Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HK1249521A1 (zh) *	2015-05-07	2018-11-02	肿瘤免疫股份有限公司	Cd24用於降低低密度脂蛋白胆固醇水平的用途
US10799558B2 (en)	2016-02-02	2020-10-13	Oncoimmune, Inc.	Use of CD24 proteins for treating leptin-deficient conditions
US10758574B2 (en)	2016-04-28	2020-09-01	The Board Of Trustees Of The Leland Stanford Junior University	Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) *	2016-12-08	2017-10-23	박문수	폐유지를 이용한 지방산 메틸에스테르 제조방법
SG11201908077XA (en) *	2017-03-07	2019-09-27	Oncoimmune Inc	Methods of use of soluble cd24 for treating systemic lupus erythematosus
CN110650749A (zh) *	2017-05-15	2020-01-03	肿瘤免疫股份有限公司	使用可溶性cd24进行神经保护和髓鞘再生的方法
EP3630158B1 (de) *	2017-05-22	2022-07-13	Oncoimmune, Inc.	Verfahren zur verwendung von löslichem cd24 zur behandlung von immunbedingten unerwünschten ereignissen in krebstherapien
US20210046154A1 (en) *	2018-03-05	2021-02-18	Oncoimmune, Inc	Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
SG11202010589YA (en) *	2018-05-14	2020-11-27	Oncoimmune Inc	Anti-cd24 compositions and uses thereof
TW202015753A (zh) *	2018-06-04	2020-05-01	美商昂科免疫公司	以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko)	2018-10-26	2023-07-24	에프. 호프만-라 로슈 아게	재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP7728747B2 (ja) *	2019-08-23	2025-08-25	サナバイオテクノロジー，インコーポレイテッド	Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) *	2019-09-12	2023-10-17	上海津曼特生物科技有限公司	一种融合蛋白及其制备方法和应用
US20250195673A1 (en) *	2020-11-30	2025-06-19	Fred Hutchinson Cancer Center	Compositions and methods for selective depletion of target molecules
CN118076625A (zh) *	2021-09-28	2024-05-24	广州昂科免疫生物技术有限公司	包含071核心肽的融合蛋白及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US5759775A (en) *	1994-10-27	1998-06-02	Genetech, Inc.	Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
CN101254302B (zh) *	1999-05-07	2011-05-11	杰南技术公司	使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
WO2001072325A1 (en) *	2000-03-29	2001-10-04	The Ohio State University Research Foundation	Methods of blocking tissue destruction by autoreactive t cells
US20030095966A1 (en) *	2000-03-29	2003-05-22	Yang Liu	Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) *	2000-03-29	2003-06-05	Yang Liu	Methods of blocking tissue destruction by autoreactive T cells
PL362324A1 (en) *	2001-02-19	2004-10-18	Merck Patent Gmbh	Artificial fusion proteins with reduced immunogenicity
US20050214290A1 (en) *	2001-03-29	2005-09-29	Yang Liu	Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) *	2001-07-13	2003-01-23	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Methods for reducing immunogenicity of polypeptides
CN100594037C (zh) *	2002-11-15	2010-03-17	Musc研究发展基金会	通过补体受体2定向的补体调节剂
AU2007242919B8 (en) *	2003-04-09	2011-11-10	F. Hoffmann-La Roche Ag	Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
ME00426B (me) *	2003-04-09	2011-10-10	Genentech Inc	Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
AU2004294547A1 (en) *	2003-11-26	2005-06-16	The Ohio State University Research Foundation	Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression
JP2008507591A (ja) *	2004-05-21	2008-03-13	ゼンコー・インコーポレイテッド	免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
WO2006053245A2 (en) *	2004-11-12	2006-05-18	Iogenetics, Llc	Retroviral vectors with introns

2011
- 2011-04-28 ES ES17183045T patent/ES2826445T3/es active Active
- 2011-04-28 EP EP11778000.7A patent/EP2563385B1/de active Active
- 2011-04-28 PL PL11778000T patent/PL2563385T3/pl unknown
- 2011-04-28 AU AU2011248540A patent/AU2011248540B2/en not_active Ceased
- 2011-04-28 EA EA201790538A patent/EA036805B8/ru unknown
- 2011-04-28 EP EP17183045.8A patent/EP3260128B1/de active Active
- 2011-04-28 EP EP20188241.2A patent/EP3845238A1/de not_active Withdrawn
- 2011-04-28 NO NO11778000A patent/NO2563385T3/no unknown
- 2011-04-28 SG SG2012077095A patent/SG184907A1/en unknown
- 2011-04-28 DK DK11778000.7T patent/DK2563385T3/da active
- 2011-04-28 PT PT171830458T patent/PT3260128T/pt unknown
- 2011-04-28 PT PT117780007T patent/PT2563385T/pt unknown
- 2011-04-28 JP JP2013508244A patent/JP5899206B2/ja not_active Expired - Fee Related
- 2011-04-28 WO PCT/US2011/034282 patent/WO2011139820A1/en not_active Ceased
- 2011-04-28 CN CN201510683408.8A patent/CN105381451B/zh not_active Expired - Fee Related
- 2011-04-28 CN CN201180021423.6A patent/CN102869369B/zh not_active Expired - Fee Related
- 2011-04-28 US US13/643,527 patent/US8808697B2/en active Active
- 2011-04-28 ES ES11778000.7T patent/ES2645262T3/es active Active
- 2011-04-28 CA CA2795823A patent/CA2795823C/en active Active
- 2011-04-28 PL PL17183045T patent/PL3260128T3/pl unknown
- 2011-04-28 EA EA201290961A patent/EA027735B1/ru unknown
- 2011-04-28 NZ NZ603196A patent/NZ603196A/en not_active IP Right Cessation
- 2011-04-28 KR KR1020127028301A patent/KR20130086126A/ko not_active Withdrawn
2012
- 2012-10-28 IL IL222739A patent/IL222739A0/en active IP Right Grant
2015
- 2015-07-09 JP JP2015137457A patent/JP6062502B2/ja not_active Expired - Fee Related
2016
- 2016-12-14 JP JP2016242313A patent/JP2017057216A/ja not_active Withdrawn
2018
- 2018-05-16 JP JP2018094404A patent/JP6526872B2/ja not_active Expired - Fee Related
2019
- 2019-05-08 JP JP2019088170A patent/JP6888221B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20130136739A1 (en)	2013-05-30
EP2563385A4 (de)	2013-10-02
US8808697B2 (en)	2014-08-19
WO2011139820A1 (en)	2011-11-10
EA036805B1 (ru)	2020-12-23
CN102869369B (zh)	2016-05-18
CN105381451B (zh)	2021-03-09
WO2011139820A8 (en)	2013-02-07
HK1176007A1 (zh)	2013-07-19
JP2017057216A (ja)	2017-03-23
PL3260128T3 (pl)	2021-02-08
EA201290961A1 (ru)	2013-04-30
JP5899206B2 (ja)	2016-04-06
EA201790538A2 (ru)	2017-07-31
IL222739A0 (en)	2012-12-31
ES2645262T3 (es)	2017-12-04
EP2563385B1 (de)	2017-08-02
CN105381451A (zh)	2016-03-09
EA036805B8 (ru)	2021-02-25
EP2563385A1 (de)	2013-03-06
EP3260128B1 (de)	2020-07-29
JP2013527168A (ja)	2013-06-27
JP2019151655A (ja)	2019-09-12
AU2011248540B2 (en)	2014-11-20
EP3845238A1 (de)	2021-07-07
ES2826445T3 (es)	2021-05-18
JP6062502B2 (ja)	2017-01-18
EA027735B1 (ru)	2017-08-31
PT2563385T (pt)	2017-11-10
EA201790538A3 (ru)	2017-11-30
JP2015187162A (ja)	2015-10-29
CN102869369A (zh)	2013-01-09
SG184907A1 (en)	2012-11-29
CA2795823C (en)	2019-06-04
CA2795823A1 (en)	2011-11-10
KR20130086126A (ko)	2013-07-31
HK1222554A1 (zh)	2017-07-07
DK2563385T3 (da)	2017-11-06
PL2563385T3 (pl)	2018-04-30
NZ603196A (en)	2014-07-25
JP2018127493A (ja)	2018-08-16
JP6888221B2 (ja)	2021-06-16
JP6526872B2 (ja)	2019-06-05
PT3260128T (pt)	2020-10-22
EP3260128A1 (de)	2017-12-27

Publication	Publication Date	Title
BR112012030039A2 (de)	2017-09-05
BR112012028408A2 (de)	2017-10-03
BR112012029986A2 (de)	2017-08-22
BR112012027808A2 (de)	2017-08-15
BR112012024897A2 (de)	2017-08-22
BR112012031500A2 (de)	2015-11-17
BR112012017960A2 (de)	2017-10-03
BR112012002126A2 (de)	2017-01-03
BR112012025482A2 (de)	2012-10-05
BR112012031826A2 (de)	2021-12-21
BR112012025577A2 (de)	2017-08-29
BR112012023249A2 (de)	2017-08-15
BR112012028186A2 (de)	2017-08-15
BR112012026403A2 (de)	2017-09-05
BR112012027945A2 (de)	2017-08-15
BR112012024872A2 (de)	2017-08-15
BR112013003284A2 (de)	2017-08-29
BR112013002646A2 (de)	2013-02-04
BR112012022788A2 (de)	2021-12-21
BR112012016895A2 (de)	2017-09-05
BR112012028859A2 (de)	2017-08-15
BR112012029562A2 (de)	2021-12-28
BR112012027756A2 (de)	2017-08-15
BR112012023744A2 (de)	2017-10-03
BR112012019465A2 (de)	2017-09-05